A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis - Trial NCT03942042
Access comprehensive clinical trial information for NCT03942042 through Pure Global AI's free database. This Phase 4 trial is sponsored by Eli Lilly and Company and is currently Completed. The study focuses on Generalized Pustular Psoriasis,Erythrodermic Psoriasis. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Eli Lilly and Company
Timeline & Enrollment
Phase 4
Jul 05, 2019
Jul 22, 2020
Primary Outcome
Maintenance Dosing Period: Number of Participants Who Improved Global Improvement Score (GIS) at Least 1 Point From Week 12 Through Week 20 and With ≤2 of GIS
Summary
The reason for this study is to see if the study drug ixekizumab is safe and effective in
 participants with generalized pustular psoriasis and erythrodermic psoriasis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03942042
Non-Device Trial